Key result
Administration of opicapone at and doses did not induce clinically significant prolongation of the QTc interval, with all upper bounds of the 1-sided.
Why the study?
Does opicapone induce clinically significant prolongation of the QTc interval in healthy adult volunteers?
RCT (n=64)
double-blind
randomized
No
Does opicapone induce clinically significant prolongation of the QTc interval in healthy adult volunteers?
Opicapone at therapeutic and supratherapeutic doses does not induce clinically significant prolongation of the QTc interval.
Answers are grounded in this paper and cite their sources.
Opicapone may be prescribed without QTc monitoring; confirms cardiac safety in this dedicated RCT.
Opicapone, a novel third-generation catechol-O-methyltransferase inhibitor for use as adjunctive therapy in levodopa-treated Parkinson's disease patients, was investigated on cardiac repolarization in healthy adult volunteers. This was a single-center, randomized, double-blind, placebo-controlled, open-label active-controlled, 4-period crossover study conducted in 64 subjects. In each period, subjects received a single oral dose of 50 mg opicapone, 800 mg opicapone, placebo, or 400 mg moxifloxacin and 24-hour 12-lead Holter monitoring was performed on day -1 (baseline) and after each single dose. After a single oral administrations of 50 and 800 mg opicapone, opicapone was the major entity in the circulation, with a median tmax of 1.5-2.0 hours. Opicapone was rapidly eliminated, with an elimination half-life of 1-2 hours. There was no clinically relevant effect of 50 and 800 mg opicapone versus placebo on cardiac depolarization or repolarization. All upper bounds of the 1-sided 95% confidence interval (CI) were below 10 milliseconds, confirming that opicapone has no QT-prolonging effect. Moxifloxacin caused an increase in the QTcI, with a lower bound of the 2-sided 95% CI always higher than 5 milliseconds, around the tmax of peak concentration, demonstrating assay sensitivity. In conclusion, administration of opicapone at therapeutic (50 mg) and supratherapeutic (800 mg) doses did not induce a clinically significant prolongation of the QTc interval.
No takes yet. Share an insight, caveat, or question.
Pinto et al. (2015) conducted an RCT in healthy adult volunteers (n=64). Opicapone vs. Placebo and 400 mg moxifloxacin was evaluated on Cardiac depolarization or repolarization (QTc interval). Administration of opicapone at and doses did not induce clinically significant prolongation of the QTc interval, with all upper bounds of the 1-sided.
Synapse has enriched 10 related papers. Consider them for comparative context: